These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 24231509)

  • 1. Atypical protein kinase Cι as a human oncogene and therapeutic target.
    Parker PJ; Justilien V; Riou P; Linch M; Fields AP
    Biochem Pharmacol; 2014 Mar; 88(1):1-11. PubMed ID: 24231509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer.
    Fields AP; Frederick LA; Regala RP
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):996-1000. PubMed ID: 17956262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent copy number gains drive PKCι expression and PKCι-dependent oncogenic signaling in human cancers.
    Liu Y; Justilien V; Fields AP; Murray NR
    Adv Biol Regul; 2020 Dec; 78():100754. PubMed ID: 32992230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota.
    Erdogan E; Lamark T; Stallings-Mann M; Lee Jamieson ; Pellecchia M; Thompson EA; Johansen T; Fields AP
    J Biol Chem; 2006 Sep; 281(38):28450-9. PubMed ID: 16861740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion.
    Butler AM; Scotti Buzhardt ML; Erdogan E; Li S; Inman KS; Fields AP; Murray NR
    Oncotarget; 2015 Jun; 6(17):15297-310. PubMed ID: 25915428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity.
    Regala RP; Weems C; Jamieson L; Copland JA; Thompson EA; Fields AP
    J Biol Chem; 2005 Sep; 280(35):31109-15. PubMed ID: 15994303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.
    Stallings-Mann M; Jamieson L; Regala RP; Weems C; Murray NR; Fields AP
    Cancer Res; 2006 Feb; 66(3):1767-74. PubMed ID: 16452237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous inhibition of atypical protein kinase‑C and mTOR impedes bladder cancer cell progression.
    Patel R; Islam SA; Bommareddy RR; Smalley T; Acevedo-Duncan M
    Int J Oncol; 2020 Jun; 56(6):1373-1386. PubMed ID: 32236625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer.
    Regala RP; Weems C; Jamieson L; Khoor A; Edell ES; Lohse CM; Fields AP
    Cancer Res; 2005 Oct; 65(19):8905-11. PubMed ID: 16204062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase C: perfectly balanced.
    Newton AC
    Crit Rev Biochem Mol Biol; 2018 Apr; 53(2):208-230. PubMed ID: 29513138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.
    Podar K; Raab MS; Chauhan D; Anderson KC
    Expert Opin Investig Drugs; 2007 Oct; 16(10):1693-707. PubMed ID: 17922632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase C and cancer: what we know and what we do not.
    Garg R; Benedetti LG; Abera MB; Wang H; Abba M; Kazanietz MG
    Oncogene; 2014 Nov; 33(45):5225-37. PubMed ID: 24336328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma.
    Zhang L; Huang J; Yang N; Liang S; Barchetti A; Giannakakis A; Cadungog MG; O'Brien-Jenkins A; Massobrio M; Roby KF; Katsaros D; Gimotty P; Butzow R; Weber BL; Coukos G
    Cancer Res; 2006 May; 66(9):4627-35. PubMed ID: 16651413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical protein kinase Cι (PKCι) promotes metastasis of esophageal squamous cell carcinoma by enhancing resistance to Anoikis via PKCι-SKP2-AKT pathway.
    Liu SG; Wang BS; Jiang YY; Zhang TT; Shi ZZ; Yang Y; Yang YL; Wang XC; Lin DC; Zhang Y; Yang H; Cai Y; Zhan QM; Wang MR
    Mol Cancer Res; 2011 Apr; 9(4):390-402. PubMed ID: 21310827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C iota: human oncogene, prognostic marker and therapeutic target.
    Fields AP; Regala RP
    Pharmacol Res; 2007 Jun; 55(6):487-97. PubMed ID: 17570678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and clinical development of novel agents that target the protein kinase C family.
    Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
    Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of oncogenic protein kinase Ciota signaling in lung adenocarcinoma.
    Erdogan E; Klee EW; Thompson EA; Fields AP
    Clin Cancer Res; 2009 Mar; 15(5):1527-33. PubMed ID: 19223491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pros and cons of targeting protein kinase C (PKC) in the management of cancer patients.
    Leskow FC; Krasnapolski MA; Urtreger AJ
    Curr Pharm Biotechnol; 2011 Nov; 12(11):1961-73. PubMed ID: 21470133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of atypical protein kinase C‑ι effectively reduces the malignancy of prostate cancer cells by downregulating the NF-κB signaling cascade.
    Apostolatos AH; Ratnayake WS; Win-Piazza H; Apostolatos CA; Smalley T; Kang L; Salup R; Hill R; Acevedo-Duncan M
    Int J Oncol; 2018 Nov; 53(5):1836-1846. PubMed ID: 30226591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Proto-oncogene PKCι regulates the alternative splicing of Bcl-x pre-mRNA.
    Shultz JC; Vu N; Shultz MD; Mba MU; Shapiro BA; Chalfant CE
    Mol Cancer Res; 2012 May; 10(5):660-9. PubMed ID: 22522453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.